English

Cellular Biomedicine Group, Inc.

EDGAR

CBMG Quarterly report (10-Q) · filed 2020-11-09

96 filing records in this dataset, filed from 2006-11-20 to 2020-11-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

32.3 thousand USD

2020 Q3 · USD

Exact inputs and evidence

Revenue: 32295 USD Source

Operating margin

-54,768.12%

2020 Q3 · %

Exact inputs and evidence

Operating Income: -17687365 USD Source
Revenue: 32295 USD Source

Operating cash flow

-13.4 million USD

2020 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -33170294 USD Source
Operating Cash Flow: -19817328 USD Source

Cash and cash equivalents: 26 million USD 2020-09-30 Source
Exact value

26028897 USD
Long-term debt including current maturities: Not available
Shares outstanding: 19.5 million shares 2020-09-30 Source
Exact value

19450353 shares

Reported share-count change

0.92% · 178 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

19272223 shares · 2019-09-30· Source
19450353 shares · 2020-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

323 thousand USD

2019-10-01 – 2020-09-30

Exact inputs and evidence

Revenue: 290655 USD · 2019-10-01 – 2019-12-31 Source
Revenue: 0 USD · 2020-01-01 – 2020-03-31 Source
Revenue: 0 USD · 2020-04-01 – 2020-06-30 Source
Revenue: 32295 USD · 2020-07-01 – 2020-09-30 Source

Net income

-54.8 million USD

2019-10-01 – 2020-09-30

Exact inputs and evidence

Net income: -12686663 USD · 2019-10-01 – 2019-12-31 Source
Net income: -11547497 USD · 2020-01-01 – 2020-03-31 Source
Net income: -13532089 USD · 2020-04-01 – 2020-06-30 Source
Net income: -17038004 USD · 2020-07-01 – 2020-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2020-11-09.

Financial data available through: 2019-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2019-12-31
Operating income: 11 of 11 periods available· newest 2019-12-31
Net income: 11 of 11 periods available· newest 2019-12-31
Operating cash flow: 11 of 11 periods available· newest 2019-12-31
capital expenditure: No compatible figures in this window
Total assets: 11 of 11 periods available· newest 2019-12-31
Total liabilities: 11 of 11 periods available· newest 2019-12-31
Current assets: 11 of 11 periods available· newest 2019-12-31
Current liabilities: 11 of 11 periods available· newest 2019-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2019-12-31
long term debt: No compatible figures in this window
Shares outstanding: 10 of 11 periods available· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+51.5%

Prior period

USD 224,403

2018-01-01 – 2018-12-31
Current period

USD 339,920

2019-01-01 – 2019-12-31

Exact inputs and evidence

339920 − 224403 = 115517 USD

224403 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
339920 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Cellular Biomedicine Group, Inc. · 2019-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Year-over-year change in Revenue: 115517 USD Concept: fundies:Revenue Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 339920 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#91990 Filing: 000165495420002065 Input fundies:Revenue: 224403 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#92105 Filing: 000165495420002065
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 11.04 million

Prior period

−USD 38.95 million

2018-01-01 – 2018-12-31
Current period

−USD 49.98 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-49984054 − -38945492 = -11038562 USD

-38945492 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-49984054 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Cellular Biomedicine Group, Inc. · 2019-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Year-over-year change in Net income: -11038562 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -49984054 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#100021 Filing: 000165495420002065 Input fundies:NetIncome: -38945492 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#100149 Filing: 000165495420002065
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 14.54 million

Prior period

−USD 25.11 million

2018-01-01 – 2018-12-31
Current period

−USD 39.65 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-39649983 − -25112999 = -14536984 USD

-25112999 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-39649983 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Cellular Biomedicine Group, Inc. · 2019-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Year-over-year change in Operating cash flow: -14536984 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -39649983 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#133382 Filing: 000165495420002065 Input fundies:OperatingCashFlow: -25112999 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#133568 Filing: 000165495420002065
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 339,920 100% of revenue
Operating costs Derived USD 51.33 million 15,101% of revenue
Operating income −USD 50.99 million −15,001% of revenue
Tax, interest and other Derived −USD 1.01 million −297% of revenue
Net income −USD 49.98 million −14,705% of revenue

Cash

Operating cash flow −USD 39.65 million −11,665% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2010 Net loss: net income was −10% of revenue.
2011 Operating loss: operating costs were 463% of revenue.
2012 Operating loss: operating costs were 175% of revenue.
2013 Operating loss: operating costs were 5,641% of revenue.
2014 Operating loss: operating costs were 2,305% of revenue.
2015 Operating loss: operating costs were 932% of revenue.
2016 Operating loss: operating costs were 4,625% of revenue.
2017 Operating loss: operating costs were 8,287% of revenue.
2018 Operating loss: operating costs were 18,150% of revenue.
2019 Operating loss: operating costs were 15,101% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2010 2010-01-01 – 2010-12-31	1741682	1430577 Derived	311105	486059 Derived	-174954	Unavailable	Source 2010-01-01 – 2010-12-31: 1741682 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: 311105 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: -174954 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -90211 USD Inspect Operating Cash Flow Open source
2011 2011-01-01 – 2011-12-31	285500	1322361 Derived	-1036861	-520447 Derived	-516414	Unavailable	Source 2011-01-01 – 2011-12-31: 285500 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -1036861 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -516414 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: 347866 USD Inspect Operating Cash Flow Open source
2012 2012-01-01 – 2012-12-31	9399256	16461055 Derived	-7061799	-30280 Derived	-7031519	Unavailable	Source 2012-01-01 – 2012-12-31: 9399256 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -7061799 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -7031519 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -7458716 USD Inspect Operating Cash Flow Open source
2013 2013-01-01 – 2013-12-31	204914	11558531 Derived	-11353617	2443416 Derived	-13797033	Unavailable	Source 2013-01-01 – 2013-12-31: 204914 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -11353617 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -13797033 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -8455364 USD Inspect Operating Cash Flow Open source
2014 2014-01-01 – 2014-12-31	564377	13006861 Derived	-12442484	3032127 Derived	-15474611	Unavailable	Source 2014-01-01 – 2014-12-31: 564377 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -12442484 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -15474611 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -9720892 USD Inspect Operating Cash Flow Open source
2015 2015-01-01 – 2015-12-31	2505423	23354393 Derived	-20848970	-1401249 Derived	-19447721	Unavailable	Source 2015-01-01 – 2015-12-31: 2505423 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -20848970 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -19447721 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -11751098 USD Inspect Operating Cash Flow Open source
2016 2016-01-01 – 2016-12-31	627930	29043264 Derived	-28415334	-206958 Derived	-28208376	Unavailable	Source 2016-01-01 – 2016-12-31: 627930 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -28415334 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -28208376 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -15867735 USD Inspect Operating Cash Flow Open source
2017 2017-01-01 – 2017-12-31	336817	27913384 Derived	-27576567	-2086257 Derived	-25490310	Unavailable	Source 2017-01-01 – 2017-12-31: 336817 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -27576567 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -25490310 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -18593392 USD Inspect Operating Cash Flow Open source
2018 2018-01-01 – 2018-12-31	224403	40730148 Derived	-40505745	-1560253 Derived	-38945492	Unavailable	Source 2018-01-01 – 2018-12-31: 224403 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -40505745 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -38945492 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -25112999 USD Inspect Operating Cash Flow Open source
2019 2019-01-01 – 2019-12-31	339920	51332104 Derived	-50992184	-1008130 Derived	-49984054	Unavailable	Source 2019-01-01 – 2019-12-31: 339920 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -50992184 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -49984054 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -39649983 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 339.9K 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Revenue	1741682	Revenue: 1741682 Open source
20112011-12-31	Revenue	285500	Revenue: 285500 Open source
20122012-12-31	Revenue	9399256	Revenue: 9399256 Open source
20132013-12-31	Revenue	204914	Revenue: 204914 Open source
20142014-12-31	Revenue	564377	Revenue: 564377 Open source
20152015-12-31	Revenue	2505423	Revenue: 2505423 Open source
20162016-12-31	Revenue	627930	Revenue: 627930 Open source
20172017-12-31	Revenue	336817	Revenue: 336817 Open source
20182018-12-31	Revenue	224403	Revenue: 224403 Open source
20192019-12-31	Revenue	339920	Revenue: 339920 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

51.5% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Year over year	3,383.4%	Revenue: 1741682 Open source Revenue: 50000 Open source
20112011-12-31	Year over year	-83.6%	Revenue: 285500 Open source Revenue: 1741682 Open source
20122012-12-31	Year over year	3,192.2%	Revenue: 9399256 Open source Revenue: 285500 Open source
20132013-12-31	Year over year	-97.8%	Revenue: 204914 Open source Revenue: 9399256 Open source
20142014-12-31	Year over year	175.4%	Revenue: 564377 Open source Revenue: 204914 Open source
20152015-12-31	Year over year	343.9%	Revenue: 2505423 Open source Revenue: 564377 Open source
20162016-12-31	Year over year	-74.9%	Revenue: 627930 Open source Revenue: 2505423 Open source
20172017-12-31	Year over year	-46.4%	Revenue: 336817 Open source Revenue: 627930 Open source
20182018-12-31	Year over year	-33.4%	Revenue: 224403 Open source Revenue: 336817 Open source
20192019-12-31	Year over year	51.5%	Revenue: 339920 Open source Revenue: 224403 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -15,001.2% 2019

Net margin -14,704.7% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Operating margin	17.9%	Operating Income: 311105 Open source Revenue: 1741682 Open source
20112011-12-31	Operating margin	-363.2%	Operating Income: -1036861 Open source Revenue: 285500 Open source
20122012-12-31	Operating margin	-75.1%	Operating Income: -7061799 Open source Revenue: 9399256 Open source
20132013-12-31	Operating margin	-5,540.7%	Operating Income: -11353617 Open source Revenue: 204914 Open source
20142014-12-31	Operating margin	-2,204.6%	Operating Income: -12442484 Open source Revenue: 564377 Open source
20152015-12-31	Operating margin	-832.2%	Operating Income: -20848970 Open source Revenue: 2505423 Open source
20162016-12-31	Operating margin	-4,525.2%	Operating Income: -28415334 Open source Revenue: 627930 Open source
20172017-12-31	Operating margin	-8,187.4%	Operating Income: -27576567 Open source Revenue: 336817 Open source
20182018-12-31	Operating margin	-18,050.4%	Operating Income: -40505745 Open source Revenue: 224403 Open source
20192019-12-31	Operating margin	-15,001.2%	Operating Income: -50992184 Open source Revenue: 339920 Open source
20102010-12-31	Net margin	-10%	Net Income: -174954 Open source Revenue: 1741682 Open source
20112011-12-31	Net margin	-180.9%	Net Income: -516414 Open source Revenue: 285500 Open source
20122012-12-31	Net margin	-74.8%	Net Income: -7031519 Open source Revenue: 9399256 Open source
20132013-12-31	Net margin	-6,733.1%	Net Income: -13797033 Open source Revenue: 204914 Open source
20142014-12-31	Net margin	-2,741.9%	Net Income: -15474611 Open source Revenue: 564377 Open source
20152015-12-31	Net margin	-776.2%	Net Income: -19447721 Open source Revenue: 2505423 Open source
20162016-12-31	Net margin	-4,492.3%	Net Income: -28208376 Open source Revenue: 627930 Open source
20172017-12-31	Net margin	-7,568%	Net Income: -25490310 Open source Revenue: 336817 Open source
20182018-12-31	Net margin	-17,355.2%	Net Income: -38945492 Open source Revenue: 224403 Open source
20192019-12-31	Net margin	-14,704.7%	Net Income: -49984054 Open source Revenue: 339920 Open source
20102010-12-31	Free cash flow margin	Not reported	Revenue: 1741682 Open source Operating Cash Flow: -90211 Open source
20112011-12-31	Free cash flow margin	Not reported	Revenue: 285500 Open source Operating Cash Flow: 347866 Open source
20122012-12-31	Free cash flow margin	Not reported	Revenue: 9399256 Open source Operating Cash Flow: -7458716 Open source
20132013-12-31	Free cash flow margin	Not reported	Revenue: 204914 Open source Operating Cash Flow: -8455364 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 564377 Open source Operating Cash Flow: -9720892 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 2505423 Open source Operating Cash Flow: -11751098 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 627930 Open source Operating Cash Flow: -15867735 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 336817 Open source Operating Cash Flow: -18593392 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 224403 Open source Operating Cash Flow: -25112999 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 339920 Open source Operating Cash Flow: -39649983 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -39.6M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Operating cash flow	-90211	Operating Cash Flow: -90211 Open source
20112011-12-31	Operating cash flow	347866	Operating Cash Flow: 347866 Open source
20122012-12-31	Operating cash flow	-7458716	Operating Cash Flow: -7458716 Open source
20132013-12-31	Operating cash flow	-8455364	Operating Cash Flow: -8455364 Open source
20142014-12-31	Operating cash flow	-9720892	Operating Cash Flow: -9720892 Open source
20152015-12-31	Operating cash flow	-11751098	Operating Cash Flow: -11751098 Open source
20162016-12-31	Operating cash flow	-15867735	Operating Cash Flow: -15867735 Open source
20172017-12-31	Operating cash flow	-18593392	Operating Cash Flow: -18593392 Open source
20182018-12-31	Operating cash flow	-25112999	Operating Cash Flow: -25112999 Open source
20192019-12-31	Operating cash flow	-39649983	Operating Cash Flow: -39649983 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Free cash flow	Unavailable	Operating Cash Flow: -90211 Open source
20112011-12-31	Free cash flow	Unavailable	Operating Cash Flow: 347866 Open source
20122012-12-31	Free cash flow	Unavailable	Operating Cash Flow: -7458716 Open source
20132013-12-31	Free cash flow	Unavailable	Operating Cash Flow: -8455364 Open source
20142014-12-31	Free cash flow	Unavailable	Operating Cash Flow: -9720892 Open source
20152015-12-31	Free cash flow	Unavailable	Operating Cash Flow: -11751098 Open source
20162016-12-31	Free cash flow	Unavailable	Operating Cash Flow: -15867735 Open source
20172017-12-31	Free cash flow	Unavailable	Operating Cash Flow: -18593392 Open source
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -25112999 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -39649983 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

42.8% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Liabilities / assets	96.5%	Total Liabilities: 1605117 Open source Total Assets: 1663980 Open source
20112011-12-31	Liabilities / assets	119.8%	Total Liabilities: 1970886 Open source Total Assets: 1645230 Open source
20122012-12-31	Liabilities / assets	8.8%	Total Liabilities: 595233 Open source Total Assets: 6751627 Open source
20132013-12-31	Liabilities / assets	12.5%	Total Liabilities: 2201653 Open source Total Assets: 17596726 Open source
20142014-12-31	Liabilities / assets	10.4%	Total Liabilities: 4529011 Open source Total Assets: 43685102 Open source
20152015-12-31	Liabilities / assets	6.3%	Total Liabilities: 3095486 Open source Total Assets: 49460422 Open source
20162016-12-31	Liabilities / assets	4%	Total Liabilities: 2734513 Open source Total Assets: 68628467 Open source
20172017-12-31	Liabilities / assets	6.3%	Total Liabilities: 3859770 Open source Total Assets: 61162296 Open source
20182018-12-31	Liabilities / assets	20.8%	Total Liabilities: 22362957 Open source Total Assets: 107581349 Open source
20192019-12-31	Liabilities / assets	42.8%	Total Liabilities: 41606609 Open source Total Assets: 97324300 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.44× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Current assets / current liabilities	0.03×	Current Assets: 49898 Open source Current Liabilities: 1605117 Open source
20112011-12-31	Current assets / current liabilities	0.31×	Current Assets: 602747 Open source Current Liabilities: 1970886 Open source
20122012-12-31	Current assets / current liabilities	7.31×	Current Assets: 4349619 Open source Current Liabilities: 595233 Open source
20132013-12-31	Current assets / current liabilities	3.44×	Current Assets: 7575008 Open source Current Liabilities: 2201653 Open source
20142014-12-31	Current assets / current liabilities	3.95×	Current Assets: 16095465 Open source Current Liabilities: 4076322 Open source
20152015-12-31	Current assets / current liabilities	5.53×	Current Assets: 16694291 Open source Current Liabilities: 3019257 Open source
20162016-12-31	Current assets / current liabilities	17.21×	Current Assets: 40692084 Open source Current Liabilities: 2364036 Open source
20172017-12-31	Current assets / current liabilities	6.47×	Current Assets: 23794846 Open source Current Liabilities: 3676121 Open source
20182018-12-31	Current assets / current liabilities	6.79×	Current Assets: 54607711 Open source Current Liabilities: 8041206 Open source
20192019-12-31	Current assets / current liabilities	1.44×	Current Assets: 34029640 Open source Current Liabilities: 23672866 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2010 2010-01-01 – 2010-12-31	−USD 174,954 Exact value Exact value: -174954 USD 2010-01-01 – 2010-12-31: -174954 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2010-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -174954 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -174954 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000135448813004464/ebig-20111231.xml#24489 Filing: 000135448813004464 The citation records this snapshot. The page link may show a newer release later.	−USD 90,211 Exact value Exact value: -90211 USD 2010-01-01 – 2010-12-31: -90211 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2010-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: -90211 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -90211 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000135448813004464/ebig-20111231.xml#85260 Filing: 000135448813004464 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2011 2011-01-01 – 2011-12-31	−USD 516,414 Exact value Exact value: -516414 USD 2011-01-01 – 2011-12-31: -516414 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2011-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -516414 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -516414 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000135448813004493/cmbg-20121231.xml#41364 Filing: 000135448813004493 The citation records this snapshot. The page link may show a newer release later.	USD 347,866 Exact value Exact value: 347866 USD 2011-01-01 – 2011-12-31: 347866 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2011-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: 347866 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 347866 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000135448813004493/cmbg-20121231.xml#74115 Filing: 000135448813004493 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2012 2012-01-01 – 2012-12-31	−USD 7.03 million Exact value Exact value: -7031519 USD 2012-01-01 – 2012-12-31: -7031519 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2012-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -7031519 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7031519 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000135448814001924/cmbg-20131231.xml#73776 Filing: 000135448814001924 The citation records this snapshot. The page link may show a newer release later.	−USD 7.46 million Exact value Exact value: -7458716 USD 2012-01-01 – 2012-12-31: -7458716 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2012-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: -7458716 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7458716 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000135448814001924/cmbg-20131231.xml#87192 Filing: 000135448814001924 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2013 2013-01-01 – 2013-12-31	−USD 13.8 million Exact value Exact value: -13797033 USD 2013-01-01 – 2013-12-31: -13797033 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2013-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -13797033 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13797033 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000135448816006531/cmbg-20151231.xml#111594 Filing: 000135448816006531 The citation records this snapshot. The page link may show a newer release later.	−USD 8.46 million Exact value Exact value: -8455364 USD 2013-01-01 – 2013-12-31: -8455364 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2013-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: -8455364 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8455364 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000135448816006531/cmbg-20151231.xml#132088 Filing: 000135448816006531 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2014 2014-01-01 – 2014-12-31	−USD 15.47 million Exact value Exact value: -15474611 USD 2014-01-01 – 2014-12-31: -15474611 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2014-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -15474611 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15474611 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495417001934/cmbg-20161231.xml#104950 Filing: 000165495417001934 The citation records this snapshot. The page link may show a newer release later.	−USD 9.72 million Exact value Exact value: -9720892 USD 2014-01-01 – 2014-12-31: -9720892 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2014-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: -9720892 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9720892 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495417001934/cmbg-20161231.xml#149434 Filing: 000165495417001934 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2015-01-01 – 2015-12-31	−USD 19.45 million Exact value Exact value: -19447721 USD 2015-01-01 – 2015-12-31: -19447721 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2015-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -19447721 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19447721 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495418002152/cmbg-20171231.xml#94575 Filing: 000165495418002152 The citation records this snapshot. The page link may show a newer release later.	−USD 11.75 million Exact value Exact value: -11751098 USD 2015-01-01 – 2015-12-31: -11751098 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2015-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: -11751098 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11751098 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495418002152/cmbg-20171231.xml#131455 Filing: 000165495418002152 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	−USD 28.21 million Exact value Exact value: -28208376 USD 2016-01-01 – 2016-12-31: -28208376 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2016-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -28208376 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28208376 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495419001756/cmbg-20181231.xml#95434 Filing: 000165495419001756 The citation records this snapshot. The page link may show a newer release later.	−USD 15.87 million Exact value Exact value: -15867735 USD 2016-01-01 – 2016-12-31: -15867735 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2016-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: -15867735 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15867735 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495419001756/cmbg-20181231.xml#125225 Filing: 000165495419001756 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 25.49 million Exact value Exact value: -25490310 USD 2017-01-01 – 2017-12-31: -25490310 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2017-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -25490310 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -25490310 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#102339 Filing: 000165495420002065 The citation records this snapshot. The page link may show a newer release later.	−USD 18.59 million Exact value Exact value: -18593392 USD 2017-01-01 – 2017-12-31: -18593392 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2017-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: -18593392 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18593392 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#133754 Filing: 000165495420002065 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 38.95 million Exact value Exact value: -38945492 USD 2018-01-01 – 2018-12-31: -38945492 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2018-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -38945492 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38945492 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#100149 Filing: 000165495420002065 The citation records this snapshot. The page link may show a newer release later.	−USD 25.11 million Exact value Exact value: -25112999 USD 2018-01-01 – 2018-12-31: -25112999 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2018-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: -25112999 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25112999 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#133568 Filing: 000165495420002065 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 49.98 million Exact value Exact value: -49984054 USD 2019-01-01 – 2019-12-31: -49984054 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cellular Biomedicine Group, Inc. · 2019-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Net Income: -49984054 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -49984054 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#100021 Filing: 000165495420002065 The citation records this snapshot. The page link may show a newer release later.	−USD 39.65 million Exact value Exact value: -39649983 USD 2019-01-01 – 2019-12-31: -39649983 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cellular Biomedicine Group, Inc. · 2019-12-31 Cellular Biomedicine Group, Inc. (edgar:1378624) Operating Cash Flow: -39649983 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:44:56Z Snapshot: 5270f0e7bdfaf090c8544e950743f8057aea40f205bd662344762f245926517c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1378624/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39649983 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/cbmg-20191231.xml#133382 Filing: 000165495420002065 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

96 filings · 2,984 latest values · 2,984 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001378624, 1378624, CBMG, edgar:1378624

Also known as CELLULAR BIOMEDICINE GROUP, INC., Cellular Biomedicine Group, Inc., EastBridge Investment Group Corp

Cellular Biomedicine Group, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation